Entrada Therapeutics (TRDA) Payables (2020 - 2026)

Entrada Therapeutics' Payables history runs 7 years deep, the most recent figure standing at $2.9 million for Q1 2026.

• In Q1 2026, Payables rose 33.91% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 33.91% YoY), while the FY2025 annual figure was $2.3 million, down 46.25% from the prior year.
• Payables was $2.9 million for Q1 2026 at Entrada Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Payables ranged from a high of $6.5 million in Q1 2023 to a low of $752000.0 in Q3 2023.
• Historically, Payables has averaged $2.9 million across 5 years, with a median of $2.5 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Payables jumped 748.44% in 2022, then slumped 60.97% in 2024.
• A 5-year view of Payables shows it stood at $6.0 million in 2022, then plunged by 45.29% to $3.3 million in 2023, then gained by 29.97% to $4.3 million in 2024, then sank by 46.25% to $2.3 million in 2025, then increased by 28.0% to $2.9 million in 2026.
• The last three Payables figures came in at $2.9 million (Q1 2026), $2.3 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.